89 results
8-K
EX-99.1
ARVN
Arvinas Inc
16 May 24
Regulation FD Disclosure
6:05am
. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has four investigational
8-K
EX-99.1
ARVN
Arvinas Inc
7 May 24
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:02am
validated and “undruggable” targets, the company has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment
8-K
EX-99.1
ARVN
Arvinas Inc
11 Apr 24
Entry into a Material Definitive Agreement
7:03am
-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has
8-K
EX-99.1
jqzk6gn4
27 Feb 24
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:02am
S-3ASR
5ubhbkcx8li6w hii
8 Dec 23
Automatic shelf registration
9:16am
8-K
EX-99.1
bcdnuz
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
o9ebtz2c g0d
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
S-3ASR
i2tkk
7 Nov 23
Automatic shelf registration
5:24pm
8-K
EX-99.1
ncpb wuzut7vve
7 Nov 23
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:03am
8-K
EX-99.1
563m4b
23 Oct 23
Regulation FD Disclosure
8:30am
8-K
EX-99.2
ykaw2cx
23 Oct 23
Regulation FD Disclosure
8:30am
8-K
EX-99.1
rla0yi34bko4 7dwn6xy
8 Aug 23
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:03am
8-K
EX-99.1
1sg8cc31c53ma
8 Jun 23
Regulation FD Disclosure
7:14am